The University of Southampton
University of Southampton Institutional Repository

The effects of recombinant human insulin-like growth factor-I/Insulin-like growth factor binding protein-3 administration on body composition and physical fitness in recreational athletes

The effects of recombinant human insulin-like growth factor-I/Insulin-like growth factor binding protein-3 administration on body composition and physical fitness in recreational athletes
The effects of recombinant human insulin-like growth factor-I/Insulin-like growth factor binding protein-3 administration on body composition and physical fitness in recreational athletes
Context:
Insulin-like growth factor-I (IGF-I) is thought to mediate many of the anabolic actions of growth hormone (GH) and there are anecdotal reports that IGF-I is misused by elite athletes. There is no published evidence regarding the effects of IGF-I administration on athletic performance.

Objective:
To investigate the effects of IGF-I administration on body composition and physical fitness in recreational athletes.

Design and Setting:
Randomised, double-blind, placebo-controlled rhIGF-I/rhIGFBP-3 administration study at Southampton General Hospital, UK.

Participants:
56 recreational athletes (30 men, 26 women)

Intervention:
Participants were randomly assigned to receive placebo, low dose rhIGF-I/rhIGFBP-3 (30 mg/day) or high dose rhIGF-I/rhIGFBP-3 (60 mg/day) for 28 days. Body composition (assessed by Dual Energy X-ray Absorptiometry) and cardiorespiratory fitness (assessed by incremental treadmill test), were measured before and immediately after treatment. Within-individual changes after treatment were analysed using paired t-tests.

Results:
There were no significant changes in body fat mass or lean body mass in women or men after administration of rhIGF-I/rhIGFBP-3 complex. There was a significant increase in maximal oxygen consumption (VO2 max) after treatment. When women and men and low and high dose treatment groups were combined, mean VO2 max increased by approximately 7% (P = 0.001). No significant change in VO2 max was observed in the placebo group.

Conclusions:
rhIGF-I/rhIGFBP-3 administration for 28 days improves aerobic performance in recreational athletes but there are no effects on body composition.
0021-972X
3126-3131
Guha, Nishan
38212040-a65e-4874-a60a-21f0ae3bdf09
Nevitt, Simon P.
c3b28987-b9cb-4c9a-96d8-dd543bbe482c
Francis, Michael
93112f9d-8b2b-454b-ab6f-7f0d286f09e0
Woodland, John A.
bb644fb2-0899-427a-af47-102d1603923a
Bohning, Dankmar
1df635d4-e3dc-44d0-b61d-5fd11f6434e1
Sonksen, Peter H.
b3cf05ef-65c2-4e9b-8d95-b7c3aaf532cd
Holt, R.I.G.
d54202e1-fcf6-4a17-a320-9f32d7024393
Guha, Nishan
38212040-a65e-4874-a60a-21f0ae3bdf09
Nevitt, Simon P.
c3b28987-b9cb-4c9a-96d8-dd543bbe482c
Francis, Michael
93112f9d-8b2b-454b-ab6f-7f0d286f09e0
Woodland, John A.
bb644fb2-0899-427a-af47-102d1603923a
Bohning, Dankmar
1df635d4-e3dc-44d0-b61d-5fd11f6434e1
Sonksen, Peter H.
b3cf05ef-65c2-4e9b-8d95-b7c3aaf532cd
Holt, R.I.G.
d54202e1-fcf6-4a17-a320-9f32d7024393

Guha, Nishan, Nevitt, Simon P., Francis, Michael, Woodland, John A., Bohning, Dankmar, Sonksen, Peter H. and Holt, R.I.G. (2015) The effects of recombinant human insulin-like growth factor-I/Insulin-like growth factor binding protein-3 administration on body composition and physical fitness in recreational athletes. Journal of Clinical Endocrinology & Metabolism, 100 (8), 3126-3131. (doi:10.1210/jc.2015-1996).

Record type: Article

Abstract

Context:
Insulin-like growth factor-I (IGF-I) is thought to mediate many of the anabolic actions of growth hormone (GH) and there are anecdotal reports that IGF-I is misused by elite athletes. There is no published evidence regarding the effects of IGF-I administration on athletic performance.

Objective:
To investigate the effects of IGF-I administration on body composition and physical fitness in recreational athletes.

Design and Setting:
Randomised, double-blind, placebo-controlled rhIGF-I/rhIGFBP-3 administration study at Southampton General Hospital, UK.

Participants:
56 recreational athletes (30 men, 26 women)

Intervention:
Participants were randomly assigned to receive placebo, low dose rhIGF-I/rhIGFBP-3 (30 mg/day) or high dose rhIGF-I/rhIGFBP-3 (60 mg/day) for 28 days. Body composition (assessed by Dual Energy X-ray Absorptiometry) and cardiorespiratory fitness (assessed by incremental treadmill test), were measured before and immediately after treatment. Within-individual changes after treatment were analysed using paired t-tests.

Results:
There were no significant changes in body fat mass or lean body mass in women or men after administration of rhIGF-I/rhIGFBP-3 complex. There was a significant increase in maximal oxygen consumption (VO2 max) after treatment. When women and men and low and high dose treatment groups were combined, mean VO2 max increased by approximately 7% (P = 0.001). No significant change in VO2 max was observed in the placebo group.

Conclusions:
rhIGF-I/rhIGFBP-3 administration for 28 days improves aerobic performance in recreational athletes but there are no effects on body composition.

Text
EarlyReleaseVersionJune2015.pdf - Other
Download (380kB)

More information

Accepted/In Press date: 1 June 2015
e-pub ahead of print date: 5 June 2015
Published date: 1 August 2015
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 377918
URI: http://eprints.soton.ac.uk/id/eprint/377918
ISSN: 0021-972X
PURE UUID: 640d4b6c-b861-48f8-aee0-a3d051e518b3
ORCID for Dankmar Bohning: ORCID iD orcid.org/0000-0003-0638-7106
ORCID for R.I.G. Holt: ORCID iD orcid.org/0000-0001-8911-6744

Catalogue record

Date deposited: 24 Jun 2015 13:21
Last modified: 18 Feb 2021 17:17

Export record

Altmetrics

Contributors

Author: Nishan Guha
Author: Simon P. Nevitt
Author: Michael Francis
Author: John A. Woodland
Author: Dankmar Bohning ORCID iD
Author: Peter H. Sonksen
Author: R.I.G. Holt ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×